Recent preclinical studies have demonstrated that neurotoxicity and CRS are decreased and CAR-T cell activity is increased after inhibition of macrophage activating and monocyte activating cytokine GM-CSF with lenzilumab87,98,99. Here, CSF2 is linked to congenital rubella syndrome.